Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1 clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program that targets aSyn, a protein that has been identified as genetically linked to Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: beta-secretase 1/Tau, a bispecific program targeting the production of amyloid beta and the spreading of Tau. Further, it is developing LF1, a protein to treat neurodegeneration; and DNL788, a small molecule product candidate for the treatment of Alzheimer's disease and ALS. Additionally, the company has various seed program, which are under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, and AbCellera Biologics. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DNLI
Previous Symbol
CUSIPN/A
Phone650-866-8548
Debt
Debt-to-Equity RatioN/A
Current Ratio12.13
Quick Ratio12.13
Price-To-Earnings
Trailing P/E Ratio-3.54
Forward P/E Ratio-15.18
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$5.29 per share
Price / Book3.93
Profitability
EPS (Most Recent Fiscal Year)($5.89)
Net Income$-88,180,000.00
Net MarginsN/A
Return on Equity-27.94%
Return on Assets-24.66%
Miscellaneous
Employees130
Outstanding Shares94,960,000
Market Cap$1.86 billion
OptionableOptionable
Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions
What is Denali Therapeutics' stock symbol?
Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."
How were Denali Therapeutics' earnings last quarter?
Denali Therapeutics Inc (NASDAQ:DNLI) announced its quarterly earnings results on Thursday, November, 8th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by $0.13. The business had revenue of $1.20 million for the quarter, compared to analyst estimates of $3 million. View Denali Therapeutics' Earnings History.
When is Denali Therapeutics' next earnings date?
What price target have analysts set for DNLI?
6 Wall Street analysts have issued 1-year price targets for Denali Therapeutics' stock. Their predictions range from $23.00 to $26.00. On average, they anticipate Denali Therapeutics' stock price to reach $24.60 in the next year. This suggests a possible upside of 18.3% from the stock's current price. View Analyst Price Targets for Denali Therapeutics.
What is the consensus analysts' recommendation for Denali Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Denali Therapeutics.
What are Wall Street analysts saying about Denali Therapeutics stock?
Here are some recent quotes from research analysts about Denali Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and 12-month PT of $25/share of DNLI after attending Denali’s R&D Day. We believe the company is approaching neurodegenerative diseases through rigorous therapeutic discovery and development, and we expect increasingly visible pipeline progress will enhance investor conviction over the next 12-18 months. The event provided a broad perspective on pipeline strategy that could address many of the historic challenges for neurodegenerative disease drug development. Our focus is currently on the small molecule programs for DNL201 in Parkinson’s disease (PD) and DNL747 in Alzheimer’s disease (AD), ALS, and MS, which are the most advanced programs." (12/7/2018)
- 2. According to Zacks Investment Research, "Denali Therapeutics Inc. is a biotechnology company. It focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and others. Denali Therapeutics Inc. is based in SOUTH SAN FRANCISCO, United States. " (8/14/2018)
Has Denali Therapeutics been receiving favorable news coverage?
News stories about DNLI stock have trended somewhat positive recently, InfoTrie reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Denali Therapeutics earned a news sentiment score of 0.6 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the company's share price in the next several days.
Who are some of Denali Therapeutics' key competitors?
Some companies that are related to Denali Therapeutics include BIO-TECHNE (TECH), bluebird bio (BLUE), Ablynx (ABLYF), argenx (ARGX), Allogene Therapeutics (ALLO), Repligen (RGEN), China Biologic Products (CBPO), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Atara Biotherapeutics (ATRA), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Rubius Therapeutics (RUBY) and Spark Therapeutics (ONCE).
Who are Denali Therapeutics' key executives?
Denali Therapeutics' management team includes the folowing people:
- Dr. Ryan J. Watts Ph.D., Co-Founder, Pres, CEO, Chief Scientific Officer & Director (Age 42)
- Mr. Alexander O. Schuth M.D., Co-Founder, COO & Sec. (Age 45)
- Dr. Marc Tessier-Lavigne, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 58)
- Mr. Steve E. Krognes, CFO, Principal Accounting Officer & Treasurer (Age 49)
- Dr. Carole Ho, Chief Medical Officer & Head of Devel. (Age 45)
When did Denali Therapeutics IPO?
(DNLI) raised $149 million in an IPO on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.
Who are Denali Therapeutics' major shareholders?
Denali Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (8.13%), Baillie Gifford & Co. (5.78%), Vanguard Group Inc. (5.08%), BlackRock Inc. (3.49%), FIL Ltd (2.94%) and Bamco Inc. NY (1.01%). Company insiders that own Denali Therapeutics stock include Carole Ho, Douglas K Bratton and Ryan J Watts. View Institutional Ownership Trends for Denali Therapeutics.
Which institutional investors are selling Denali Therapeutics stock?
DNLI stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, FMR LLC, Virtus ETF Advisers LLC, Allianz Asset Management GmbH, Patriot Financial Group Insurance Agency LLC, Mitsubishi UFJ Trust & Banking Corp, Legal & General Group Plc and D.A. Davidson & CO.. Company insiders that have sold Denali Therapeutics company stock in the last year include Carole Ho and Ryan J Watts. View Insider Buying and Selling for Denali Therapeutics.
Which institutional investors are buying Denali Therapeutics stock?
DNLI stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Bank of New York Mellon Corp, Baillie Gifford & Co., Caxton Associates LP, Swiss National Bank, Morgan Stanley and Teachers Advisors LLC. View Insider Buying and Selling for Denali Therapeutics.
How do I buy shares of Denali Therapeutics?
Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Denali Therapeutics' stock price today?
One share of DNLI stock can currently be purchased for approximately $20.80.
How big of a company is Denali Therapeutics?
Denali Therapeutics has a market capitalization of $1.86 billion. The company earns $-88,180,000.00 in net income (profit) each year or ($5.89) on an earnings per share basis. Denali Therapeutics employs 130 workers across the globe.
What is Denali Therapeutics' official website?
How can I contact Denali Therapeutics?
Denali Therapeutics' mailing address is 151 OYSTER POINT BLVD. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-866-8548.
MarketBeat Community Rating for Denali Therapeutics (NASDAQ DNLI)
MarketBeat's community ratings are surveys of what our community members think about Denali Therapeutics and other stocks. Vote "Outperform" if you believe DNLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DNLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
